144 related articles for article (PubMed ID: 20677100)
1. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer.
Neal J; Wakelee H
Curr Opin Mol Ther; 2010 Aug; 12(4):487-95. PubMed ID: 20677100
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
Mita AC; Takimoto CH; Mita M; Tolcher A; Sankhala K; Sarantopoulos J; Valdivieso M; Wood L; Rasmussen E; Sun YN; Zhong ZD; Bass MB; Le N; LoRusso P
Clin Cancer Res; 2010 Jun; 16(11):3044-56. PubMed ID: 20501621
[TBL] [Abstract][Full Text] [Related]
3. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases.
Oliner JD; Bready J; Nguyen L; Estrada J; Hurh E; Ma H; Pretorius J; Fanslow W; Nork TM; Leedle RA; Kaufman S; Coxon A
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2170-80. PubMed ID: 22410553
[TBL] [Abstract][Full Text] [Related]
4. AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.
Robson EJ; Ghatage P
Expert Opin Investig Drugs; 2011 Feb; 20(2):297-304. PubMed ID: 21210755
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Herbst RS; Hong D; Chap L; Kurzrock R; Jackson E; Silverman JM; Rasmussen E; Sun YN; Zhong D; Hwang YC; Evelhoch JL; Oliner JD; Le N; Rosen LS
J Clin Oncol; 2009 Jul; 27(21):3557-65. PubMed ID: 19546406
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.
Doi T; Ohtsu A; Fuse N; Yoshino T; Tahara M; Shibayama K; Takubo T; Weinreich DM
Cancer Chemother Pharmacol; 2013 Jan; 71(1):227-35. PubMed ID: 23124648
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.
Wu B; Johnson J; Soto M; Ponce M; Calamba D; Sun YN
Pharm Res; 2012 Apr; 29(4):1057-65. PubMed ID: 22189693
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Diamond JR; Wu B; Agarwal N; Bowles DW; Lam ET; Werner TL; Rasmussen E; Gamelin E; Soto F; Friberg G; Sun YN; Sharma S
Invest New Drugs; 2015 Jun; 33(3):691-9. PubMed ID: 25895965
[TBL] [Abstract][Full Text] [Related]
9. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
Weeraratne DK; Lofgren J; Dinnogen S; Swanson SJ; Zhong ZD
J Immunol Methods; 2013 Oct; 396(1-2):44-55. PubMed ID: 23933325
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.
Dowlati A; Vlahovic G; Natale RB; Rasmussen E; Singh I; Hwang YC; Rossi J; Bass MB; Friberg G; Pickett CA
Clin Cancer Res; 2016 Sep; 22(18):4574-84. PubMed ID: 27076631
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
Moore KN; Sill MW; Tenney ME; Darus CJ; Griffin D; Werner TL; Rose PG; Behrens R
Gynecol Oncol; 2015 Sep; 138(3):513-8. PubMed ID: 26171911
[TBL] [Abstract][Full Text] [Related]
13. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
14. Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
Marchetti C; Gasparri ML; Ruscito I; Palaia I; Perniola G; Carrone A; Farooqi AA; Pecorini F; Muzii L; Panici PB
Crit Rev Oncol Hematol; 2015 Jun; 94(3):302-10. PubMed ID: 25783620
[TBL] [Abstract][Full Text] [Related]
15. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.
Gerald D; Chintharlapalli S; Augustin HG; Benjamin LE
Cancer Res; 2013 Mar; 73(6):1649-57. PubMed ID: 23467610
[TBL] [Abstract][Full Text] [Related]
16. Targeting angiopoietin-2 signaling in cancer therapy.
Eroglu Z; Stein CA; Pal SK
Expert Opin Investig Drugs; 2013 Jul; 22(7):813-25. PubMed ID: 23621441
[TBL] [Abstract][Full Text] [Related]
17. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.
Coxon A; Bready J; Min H; Kaufman S; Leal J; Yu D; Lee TA; Sun JR; Estrada J; Bolon B; McCabe J; Wang L; Rex K; Caenepeel S; Hughes P; Cordover D; Kim H; Han SJ; Michaels ML; Hsu E; Shimamoto G; Cattley R; Hurh E; Nguyen L; Wang SX; Ndifor A; Hayward IJ; Falcón BL; McDonald DM; Li L; Boone T; Kendall R; Radinsky R; Oliner JD
Mol Cancer Ther; 2010 Oct; 9(10):2641-51. PubMed ID: 20937592
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
20. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Oliner J; Min H; Leal J; Yu D; Rao S; You E; Tang X; Kim H; Meyer S; Han SJ; Hawkins N; Rosenfeld R; Davy E; Graham K; Jacobsen F; Stevenson S; Ho J; Chen Q; Hartmann T; Michaels M; Kelley M; Li L; Sitney K; Martin F; Sun JR; Zhang N; Lu J; Estrada J; Kumar R; Coxon A; Kaufman S; Pretorius J; Scully S; Cattley R; Payton M; Coats S; Nguyen L; Desilva B; Ndifor A; Hayward I; Radinsky R; Boone T; Kendall R
Cancer Cell; 2004 Nov; 6(5):507-16. PubMed ID: 15542434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
